# A Single-Center, Open-Label, Randomized, 3-Treatment Crossover Bioavailability Study of Single Oral Doses of E5501 Old Tablet Formulation Under Fasted Conditions and a New Tablet Formulation Under Fed and Fasted Conditions in Healthy Subjects

> **NCT01260155** · PHASE1 · COMPLETED · sponsor: **Eisai Inc.** · enrollment: 16 (actual)

## Conditions studied

- Healthy Subjects

## Interventions

- **DRUG:** E5501
- **DRUG:** E5501
- **DRUG:** E5501

## Key facts

- **NCT ID:** NCT01260155
- **Lead sponsor:** Eisai Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-01
- **Primary completion:** 2010-06
- **Final completion:** 2010-06
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2013-11-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01260155

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01260155, "A Single-Center, Open-Label, Randomized, 3-Treatment Crossover Bioavailability Study of Single Oral Doses of E5501 Old Tablet Formulation Under Fasted Conditions and a New Tablet Formulation Under Fed and Fasted Conditions in Healthy Subjects". Retrieved via AI Analytics 2026-06-13 from https://api.ai-analytics.org/clinical/NCT01260155. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*